Mechanism of Action: Hsp90 (heat shock protein 90) inhibition
Indication: Solid Tumors
How this therapy can help
Onalespib (AT13387) is a targeted inhibitor of Hsp90, a heat shock protein. Heat shock proteins are hypothesized to support the growth and proliferation of many cancer cells. Hsp90 acts as a “molecular chaperone” stabilizing and preventing the breakdown of key cancer-forming (oncogenic) proteins that are collectively referred to as “clients”.
Onalespib has the potential to control the proliferation of multiple solid tumors and hematological malignancies where uncontrolled cell growth is dependent on the interaction between Hsp90 and its client proteins. These include tumor types that have become resistant to initial therapy. Astex is pursuing an approach based on the observation that the addition of onalespib to a molecularly targeted agent may delay the emergence of resistance to the agent, and hence prolong the window of therapeutic benefit.
Onalespib is currently being evaluated via a CRADA with the National Cancer Institute (NCI) in various tumor types, and also in a Phase 1/2 clinical study in combination with AT7519, Astex’s CDK inhibitor.
View clinical studies and status
View Presentations and Publications